Insider Activity: Daniel Giannini an Insider in NxStage Medical, Inc. (NASDAQ:NXTM) Unloaded 6,449 Shares

November 23, 2016 - By Linda Rogers

Insider Activity: Daniel Giannini an Insider in NxStage Medical, Inc. (NASDAQ:NXTM) Unloaded 6,449 Shares

Daniel Giannini Insider Sell

Calculated with average price per share of $26.0, Daniel Giannini, the Nxstage Medical Inc’s shareholder sold 6,449 shares of Nxstage Medical Inc worth approximately $167,416 U.S. Dollars. Presently, Daniel Giannini has rights to 63,193 shares or around 0.10% of the company’s total market cap.

NxStage Medical, Inc. (NASDAQ:NXTM) Ratings Coverage

Out of 6 analysts covering NxStage Medical (NASDAQ:NXTM), 5 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 83% are positive. $30 is the highest target while $14 is the lowest. The $23.10 average target is -5.68% below today’s ($24.49) stock price. NxStage Medical has been the topic of 7 analyst reports since November 4, 2015 according to StockzIntelligence Inc. The stock has “Outperform” rating given by Northland Capital on Tuesday, June 28. BTIG Research initiated the stock with “Buy” rating in Friday, December 18 report. The stock of NxStage Medical, Inc. (NASDAQ:NXTM) earned “Overweight” rating by Piper Jaffray on Thursday, March 31. As per Tuesday, August 2, the company rating was maintained by Canaccord Genuity. As per Friday, December 11, the company rating was initiated by Sterne Agee CRT.

Insitutional Activity: The institutional sentiment increased to 1.2 in Q2 2016. Its up 0.23, from 0.97 in 2016Q1. The ratio improved, as 22 funds sold all NxStage Medical, Inc. shares owned while 45 reduced positions. 26 funds bought stakes while 39 increased positions. They now own 61.50 million shares or 4.11% more from 59.07 million shares in 2016Q1.

Ameriprise Fincl holds 332,926 shares or 0% of its portfolio. Manufacturers Life Ins The last reported 43,555 shares in the company. Swiss Bank & Trust, a Switzerland-based fund reported 106,800 shares. California State Teachers Retirement System has 133,515 shares for 0.01% of their US portfolio. Barnett And Company last reported 0.01% of its portfolio in the stock. Prudential Fincl has 501,096 shares for 0.02% of their US portfolio. Portolan Cap Mngmt Ltd Limited Liability Company last reported 0.67% of its portfolio in the stock. Millennium Ltd Liability Company has 0.07% invested in the company for 1.43 million shares. D E Shaw accumulated 0.01% or 244,348 shares. Delta Lloyd Nv holds 0.13% of its portfolio in NxStage Medical, Inc. (NASDAQ:NXTM) for 175,000 shares. Moreover, Credit Suisse Ag has 0% invested in NxStage Medical, Inc. (NASDAQ:NXTM) for 78,203 shares. Sectoral Asset Inc has invested 4.09% of its portfolio in NxStage Medical, Inc. (NASDAQ:NXTM). Susquehanna Group Incorporated Llp accumulated 30,891 shares or 0% of the stock. Tudor Corp Et Al has invested 0.01% of its portfolio in NxStage Medical, Inc. (NASDAQ:NXTM). Aqr Capital Mngmt Ltd Liability Corporation, a Connecticut-based fund reported 18,387 shares.

Insider Transactions: Since September 12, 2016, the stock had 0 buys, and 6 insider sales for $1.07 million net activity. 4,300 shares were sold by TOWSE MATTHEW W, worth $112,789 on Monday, November 21. 3,000 shares were sold by Swan Winifred L, worth $76,530. On Thursday, November 17 the insider Turk Joseph E Jr sold $25,970. MOORE CRAIG W sold $69,930 worth of NxStage Medical, Inc. (NASDAQ:NXTM) on Monday, September 12. $191,325 worth of NxStage Medical, Inc. (NASDAQ:NXTM) was sold by Burbank Jeffrey H on Tuesday, November 22.

The stock decreased 5.19% or $1.34 during the last trading session, hitting $24.49. About 676,148 shares traded hands or 74.69% up from the average. NxStage Medical, Inc. (NASDAQ:NXTM) has risen 53.93% since April 21, 2016 and is uptrending. It has outperformed by 48.60% the S&P500.

NxStage Medical, Inc. is a medical technology company. The company has a market cap of $1.56 billion. The Firm is engaged in the development, manufacturing and marketing of services and products for patients suffering from chronic or acute kidney failure. It currently has negative earnings. The Firm operates through three divisions: System One, In-Center and Services.

According to Zacks Investment Research, “NxStage Medical, Inc. is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure.”

More recent NxStage Medical, Inc. (NASDAQ:NXTM) news were published by: Fool.com which released: “Here’s Why NxStage Medical, Inc.’s Stock Is Popping Today” on November 03, 2016. Also Fool.com published the news titled: “Home and Critical Care Drive NxStage Medical, Inc. Q2 Improvement” on August 04, 2016. Fool.com‘s news article titled: “Why NxStage Medical, Inc. Guided Lower Today” with publication date: February 10, 2016 was also an interesting one.

NXTM Company Profile

NxStage Medical, Inc., incorporated on October 20, 1998, is a medical technology company. The Firm is engaged in the development, manufacturing and marketing of services and products for patients suffering from chronic or acute kidney failure. The Firm operates through three divisions: System One, In-Center and Services. The Firm offers its services and products to various markets, such as home, critical care and in-center. The Company’s primary product, the System One, delivers the therapeutic flexibility and clinical benefits associated with dialysis machines that can be used by healthcare professionals and trained lay users alike in various settings, including patient homes, as well as traditional care settings, such as hospitals and dialysis centers. The Firm operates NxStage Kidney Care dialysis centers that treat end-stage renal disease patients directly.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>